Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1Dermatologic 1

Conditions

Skin Neoplasms 1

Interventions

pembrolizumab 69Nivolumab 57Ipilimumab 36Specimen Handling 32Magnetic Resonance Spectroscopy 25Cyclophosphamide 23Biopsy 18cemiplimab 14fludarabine 13relatlimab 11binimetinib 11Opdualag 11CTLA-4 Antigen 11trametinib 10fludarabine phosphate 10Radiosurgery 10avelumab 9Radiotherapy 9lifileucel 8dabrafenib 8Blood Specimen Collection 8atezolizumab 7aldesleukin 7Paclitaxel 7encorafenib 6X-Rays 6Standard of Care 6Interleukin-2 6Immunoglobulin G 6HhAntag691 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
oxycodone-acetaminophen × Dermatologic × 90 days × Clear all
NCT07575230 2026-05-11

Suzetrigine vs Norco-postoperative Mohs Pain

Baylor Research Institute

Phase 4 Enrolling by invitation
75 enrolled
Dermatologic

Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡